<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00254553</url>
  </required_header>
  <id_info>
    <org_study_id>P05815</org_study_id>
    <secondary_id>P05815</secondary_id>
    <secondary_id>169001</secondary_id>
    <nct_id>NCT00254553</nct_id>
  </id_info>
  <brief_title>A Study to Test a Measure of Symptoms of Older Men With Low Testosterone On and Off Testosterone Replacement Treatment (P05815)</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Two Period Cross Over Trial to Validate Patient-Reported Outcome Measures for Use in Men With Late Onset Hypogonadism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypogonadal males, particularly those whose condition manifested later in life, may&#xD;
      experience common symptoms associated with their hypogonadism. Questionnaires developed to&#xD;
      assess these symptoms need to be tested. The primary purpose of this study is to test or&#xD;
      validate the Patient-Reported Symptom Measure, Androgen Deficiency Quality of Life&#xD;
      Questionnaire and the Patient Global Impression Scale.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Recruitment issues&#xD;
  </why_stopped>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">January 2007</completion_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient -reported outcome measures</measure>
    <time_frame>Baseline and after six weeks of treatment or placebo</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Hypogonadism</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Testim 1% (testosterone gel)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testim 1% (testosterone gel)</intervention_name>
    <description>Testim_ 100 mg: two tubes of 50 mg of Testim_per day</description>
    <arm_group_label>Arm 1</arm_group_label>
    <other_name>Testim</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>two tubes of placebo per day</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Men with late-onset hypogonadism who are either on testosterone treatment or naïve of&#xD;
        treatment:&#xD;
&#xD;
          -  have symptoms of androgen deficiency at screening (after wash-out if applicable) i.e.&#xD;
             with a positive score on the Androgen Deficiency in the Aging Male (ADAM)&#xD;
             Questionnaire (a &quot;yes&quot; answer to questions 1 or 7 or any three other questions).&#xD;
&#xD;
          -  morning total T levels of &lt;=3 ng/mL (&lt;=300 ng/dL; &lt;=10.4 nmol/l) on two separate days&#xD;
             prior to randomization (after appropriate wash-out, if applicable).&#xD;
&#xD;
          -  calculated free T &lt;=0.074 ng/mL.&#xD;
&#xD;
          -  at least 50 and at most 75 years of age.&#xD;
&#xD;
          -  BMI of at least 18 kg/m^2 or at most 32 kg/m^2&#xD;
&#xD;
        Inclusion Criteria for Normogonadal Men:&#xD;
&#xD;
          -  morning total T levels &lt;=3 ng/mL (&lt;=300 ng/dL; &lt;=10.4 nmol/L).&#xD;
&#xD;
          -  calculated free T &lt;=0.074 ng/mL.&#xD;
&#xD;
          -  at least 50 and at most 75 years of age.&#xD;
&#xD;
          -  BMI of at least 18 kg/m^2 or at most 32 kg/m^2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History or current diagnosis of prostate cancer or any clinically significant finding&#xD;
             on prostate examination&#xD;
&#xD;
          -  Severe obstructive symptoms of benign prostate hypertrophy&#xD;
&#xD;
          -  Prostate specific antigen (PSA) levels greater than 4 ng/mL at screening&#xD;
&#xD;
          -  History or current diagnosis of carcinoma of the breast&#xD;
&#xD;
          -  Known chronic polycythemia and/or hematocrit greater than 50% at screening&#xD;
&#xD;
          -  Treatment-naïve subjects with hyperprolactinemia at screening (serum prolactin level&#xD;
             &gt;=50 ng/mL)&#xD;
&#xD;
          -  Hematological or biochemical values at screening outside the reference ranges&#xD;
             considered as clinically significant in the opinion of the investigator&#xD;
&#xD;
          -  clinically significant abnormal physical finding prior to randomization&#xD;
&#xD;
          -  sensitive to trial medication or its components&#xD;
&#xD;
          -  History or presence of hepatic or renal disorder considered as clinically relevant in&#xD;
             the opinion of the investigator.&#xD;
&#xD;
        Exclusion Criteria for Normogonadal Men:&#xD;
&#xD;
          -  Presence or previous diagnosis of androgen deficiency.&#xD;
&#xD;
          -  Previous or present use of testosterone preparations&#xD;
&#xD;
          -  Use of medication within the 12 weeks prior to the visit that may interfere with the&#xD;
             objectives of the trial: hypothalamic/pituitary hormones and analogues (e.g.,&#xD;
             gonadotropins, ACTH, STH, Gn-RH agonists and antagonists, etc.); sex steroid&#xD;
&#xD;
          -  Any other disease that in the opinion of the investigator might compromise or confound&#xD;
             the subject's symptomatology (e.g., presence of clinically significant depression or&#xD;
             other psychiatric disorders, unstable endocrine disorder, sleep apnea, cardiovascular&#xD;
             and cerebrovascular diseases, etc.)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>November 14, 2005</study_first_submitted>
  <study_first_submitted_qc>November 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2005</study_first_posted>
  <last_update_submitted>December 11, 2015</last_update_submitted>
  <last_update_submitted_qc>December 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypogonadism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

